

# Marica Eoli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9452882/publications.pdf>

Version: 2024-02-01

132  
papers

8,883  
citations

109264  
35  
h-index

45285  
90  
g-index

136  
all docs

136  
docs citations

136  
times ranked

14308  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	13.5	3,979
2	Clonal evolution of glioblastoma under therapy. Nature Genetics, 2016, 48, 768-776.	9.4	591
3	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2019, 20, 110-119.	5.1	238
4	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. Clinical Cancer Research, 2015, 21, 3307-3317.	3.2	230
5	Fluorescein-Guided Surgery for Resection of High-Grade Gliomas: A Multicentric Prospective Phase II Study (FLUOGLIO). Clinical Cancer Research, 2018, 24, 52-61.	3.2	162
6	The molecular landscape of glioma in patients with Neurofibromatosis 1. Nature Medicine, 2019, 25, 176-187.	15.2	145
7	Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival. Clinical Cancer Research, 2007, 13, 2606-2613.	3.2	144
8	Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. American Journal of Human Genetics, 2018, 102, 69-87.	2.6	144
9	Is fluorescein-guided technique able to help in resection of high-grade gliomas?. Neurosurgical Focus, 2014, 36, E5.	1.0	133
10	Overlapping phenotypes in complex spastic paraplegias SPG11, SPG15, SPG35 and SPG48. Brain, 2014, 137, 1907-1920.	3.7	133
11	Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. Journal of Neuro-Oncology, 2003, 62, 297-303.	1.4	131
12	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro-Oncology, 2020, 22, 684-693.	0.6	126
13	Fluorescein-guided surgery for grade IV gliomas with a dedicated filter on the surgical microscope: preliminary results in 12 cases. Acta Neurochirurgica, 2013, 155, 1277-1286.	0.9	124
14	Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. Neuromuscular Disorders, 2000, 10, 391-397.	0.3	112
15	High-Resolution Genomic Copy Number Profiling of Glioblastoma Multiforme by Single Nucleotide Polymorphism DNA Microarray. Molecular Cancer Research, 2009, 7, 665-677.	1.5	91
16	Double-Blind Trial of Dexamethasone versus Methylprednisolone in Multiple Sclerosis Acute Relapses. European Neurology, 1994, 34, 199-203.	0.6	80
17	Clinical spectrum of individuals with pathogenic F1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. Human Mutation, 2020, 41, 299-315.	1.1	80
18	NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget, 2012, 3, 723-734.	0.8	77

#	ARTICLE	IF	CITATIONS
19	Fluorescein-guided surgery for malignant gliomas: a review. <i>Neurosurgical Review</i> , 2014, 37, 547-557.	1.2	74
20	CXCL12 in Malignant Glial Tumors: A Possible Role in Angiogenesis and Cross-Talk between Endothelial and Tumoral Cells. <i>Journal of Neuro-Oncology</i> , 2004, 67, 305-317.	1.4	72
21	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1304-1312.	0.6	71
22	Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients. <i>Journal of Neuro-Oncology</i> , 2004, 66, 203-208.	1.4	64
23	The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. <i>Onc Immunology</i> , 2013, 2, e23401.	2.1	56
24	Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 <sup>+</sup> T cell activation in the presence of adjuvant temozolomide. <i>Onc Immunology</i> , 2018, 7, e1412901.	2.1	54
25	CXCL12 Expression is Predictive of a Shorter Time to Tumor Progression in Low-Grade Glioma: A Single-Institution Study in 50 Patients. <i>Journal of Neuro-Oncology</i> , 2005, 74, 287-293.	1.4	53
26	Expression of MATH1, a marker of cerebellar granule cell progenitors, identifies different medulloblastoma sub-types. <i>Neuroscience Letters</i> , 2004, 370, 180-185.	1.0	51
27	Reclassification of oligoastrocytomas by loss of heterozygosity studies. <i>International Journal of Cancer</i> , 2006, 119, 84-90.	2.3	51
28	A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. <i>Neuro-Oncology</i> , 2021, 23, 264-276.	0.6	48
29	Double-Blind Randomized Trial of ACTH versus Dexamethasone versus Methylprednisolone in Multiple Sclerosis Bouts. <i>European Neurology</i> , 1989, 29, 10-14.	0.6	47
30	Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature. <i>Neurosurgical Review</i> , 2016, 39, 37-46.	1.2	45
31	A double blind study on azathioprine efficacy in multiple sclerosis: final report. <i>Journal of Neurology</i> , 1993, 240, 295-298.	1.8	42
32	Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?. <i>Journal of Neuro-Oncology</i> , 2008, 88, 105-113.	1.4	42
33	Predictors of survival and effect of short (40ÂGy) or standard-course (60ÂGy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , 2015, 125, 359-367.	1.4	42
34	Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions. <i>Neuro-Oncology</i> , 2020, 22, 1614-1624.	0.6	41
35	Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2005, 72, 125-131.	1.4	39
36	Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2008, 87, 143-151.	1.4	35

#	ARTICLE	IF	CITATIONS
37	Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. <i>Journal of Neuro-Oncology</i> , 2016, 126, 279-288.	1.4	33
38	Management of epilepsy in brain tumors. <i>Neurological Sciences</i> , 2019, 40, 2217-2234.	0.9	33
39	Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. <i>Annals of Neurology</i> , 2002, 52, 842-845.	2.8	32
40	Headache in brain tumours: a symptom to reappraise critically. <i>Neurological Sciences</i> , 2004, 25, s143-s147.	0.9	32
41	Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 115-120.	1.1	31
42	Instability of mitochondrial DNA and MRI and clinical correlations in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2005, 74, 87-90.	1.4	29
43	VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 121, 499-504.	1.4	29
44	Stroke-like events after brain radiotherapy: a large series with long-term follow-up. <i>European Journal of Neurology</i> , 2019, 26, 639-650.	1.7	29
45	Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan. <i>PLoS ONE</i> , 2013, 8, e74345.	1.1	28
46	Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. <i>Italian Journal of Neurological Sciences</i> , 1999, 20, 43-48.	0.1	26
47	Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma. <i>Neurological Sciences</i> , 2002, 23, 219-224.	0.9	26
48	Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1990, 53, 554-557.	0.9	25
49	Cisplatin and BCNU chemotherapy in primary glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2009, 94, 57-62.	1.4	25
50	FABP4 is a candidate marker of cerebellar liponeurocytomas. <i>Journal of Neuro-Oncology</i> , 2012, 108, 513-519.	1.4	25
51	126 novel mutations in Italian patients with neurofibromatosis type 1. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2015, 3, 513-525.	0.6	25
52	Combined chemotherapy and radiotherapy for intracranial germinomas in adult patients: a single-institution study. <i>Journal of Neuro-Oncology</i> , 2005, 71, 271-276.	1.4	24
53	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 205-210.	1.4	24
54	Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients. <i>Cancer Letters</i> , 1999, 146, 169-172.	3.2	22

#	ARTICLE	IF	CITATIONS
55	Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2009, 95, 61-64.	1.4	22
56	DNA Microarray Analysis Identifies <i>CKS2</i> and <i>LEPR</i> as Potential Markers of Meningioma Recurrence. <i>Oncologist</i> , 2011, 16, 1440-1450.	1.9	22
57	Immunological monitoring of azathioprine treatment in multiple sclerosis patients. <i>Journal of Neurology</i> , 1997, 244, 167-174.	1.8	21
58	Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. <i>Journal of Neuro-Oncology</i> , 2001, 54, 39-47.	1.4	21
59	Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO). <i>Cancers</i> , 2021, 13, 2773.	1.7	21
60	Systemic Temozolomide Combined with Loco-regional Mitoxantrone in Treating Recurrent Glioblastoma. <i>Journal of Neuro-Oncology</i> , 2005, 75, 215-220.	1.4	20
61	Defining EGFR amplification status for clinical trial inclusion. <i>Neuro-Oncology</i> , 2019, 21, 1263-1272.	0.6	20
62	Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 4478-4484.	3.2	20
63	High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 831-842.	2.0	20
64	Serial evoked potentials in multiple sclerosis bouts. Relation to steroid treatment. <i>Italian Journal of Neurological Sciences</i> , 1994, 15, 333-340.	0.1	19
65	Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience. <i>Journal of Neuro-Oncology</i> , 2007, 82, 273-279.	1.4	19
66	Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype-Phenotype Correlations in a Large Independent Cohort. <i>Cancers</i> , 2019, 11, 1838.	1.7	19
67	The myelin basic protein gene is not a major susceptibility locus for multiple sclerosis in Italian patients. <i>Journal of Neurology</i> , 1994, 241, 615-619.	1.8	18
68	Evidence of Linkage between Susceptibility to Multiple Sclerosis and HLA-Class II Loci in Italian Multiplex Families. <i>European Journal of Human Genetics</i> , 1995, 3, 303-311.	1.4	18
69	Local drug delivery in recurrent malignant gliomas. <i>Neurological Sciences</i> , 2005, 26, s37-s39.	0.9	17
70	ABCC3 Expressed by CD56dim CD16+ NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5886.	1.8	17
71	Parametric Response Maps of Perfusion MRI May Identify Recurrent Glioblastomas Responsive to Bevacizumab and Irinotecan. <i>PLoS ONE</i> , 2014, 9, e90535.	1.1	17
72	A Subpopulation of Circulating Endothelial Cells Express CD109 and is Enriched in the Blood of Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e114713.	1.1	17

#	ARTICLE	IF	CITATIONS
73	ANALYSIS OF HLA-CLASS II DQA1, DQB1, DRB1 and DPB1 IN ITALIAN MULTIPLE SCLEROSIS PATIENTS. International Journal of Immunogenetics, 1995, 22, 171-178.	1.2	16
74	Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study. Italian Journal of Neurological Sciences, 1998, 19, 32-36.	0.1	16
75	Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. Neuro-Oncology Advances, 2019, 1, vdz022.	0.4	16
76	Genetic signature of adult gliomas and correlation with MRI features. Expert Review of Molecular Diagnostics, 2009, 9, 709-720.	1.5	15
77	Presence of T-cell subset abnormalities in newly diagnosed cases of multiple sclerosis and relationship with short-term clinical activity. Journal of Neurology, 1993, 240, 79-82.	1.8	14
78	Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors. Cancer Chemotherapy and Pharmacology, 1999, 43, 178-179.	1.1	14
79	Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. Molecular Cancer, 2013, 12, 160.	7.9	14
80	Non-Coding RNA and Tumor Development in Neurofibromatosis Type 1: ANRIL Rs2151280 Is Associated with Optic Glioma Development and a Mild Phenotype in Neurofibromatosis Type 1 Patients. Genes, 2019, 10, 892.	1.0	14
81	CSF T-cell subsets in multiple sclerosis: Relationship to cerebrospinal fluid myelin basic protein and clinical activity. Journal of Neurology, 1989, 236, 336-339.	1.8	13
82	HLA antigens in Italian multiple sclerosis patients. Italian Journal of Neurological Sciences, 1991, 12, 81-86.	0.1	13
83	No linkage between multiple sclerosis and the T cell receptor $\beta$ chain locus. Journal of the Neurological Sciences, 1994, 124, 32-37.	0.3	13
84	Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). European Journal of Cancer, 2021, 155, 179-190.	1.3	13
85	Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma. Journal of Clinical Medicine, 2019, 8, 2007.	1.0	12
86	Racemose neurocysticercosis after chronic meningitis: effect of medical treatment. Clinical Neurology and Neurosurgery, 1995, 97, 50-54.	0.6	10
87	Meningo-cortical calcifying angiomas and celiac disease. Clinical Neurology and Neurosurgery, 1998, 100, 209-215.	0.6	10
88	Molecular markers of gliomas: a clinical approach. Neurological Research, 2006, 28, 538-541.	0.6	10
89	LTK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX-M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410. Neuro-Oncology, 2017, 19, vi316-vi316.	0.6	10
90	Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma. Frontiers in Oncology, 2021, 11, 747690.	1.3	10

#	ARTICLE	IF	CITATIONS
91	Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux- <sup>®</sup> M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).. Journal of Clinical Oncology, 2018, 36, 2023-2023.	0.8	10
92	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. Oncotarget, 2017, 8, 55575-55581.	0.8	10
93	HLA and multiple sclerosis in Italy: a review of the literature. Journal of Neurology, 1990, 237, 441-444.	1.8	9
94	Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas. Journal of Neuro-Oncology, 2000, 49, 71-75.	1.4	9
95	Embryonal tumors in the adult population: implications in therapeutic planning. Neurological Sciences, 2000, 21, 23-30.	0.9	9
96	Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report. Neurological Sciences, 2002, 23, 257-258.	0.9	9
97	Biopsy-proven primary angiitis of the central nervous system mimicking leukodystrophy: A case report and review of the literature. Journal of Clinical Neuroscience, 2019, 64, 42-44.	0.8	9
98	EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. Neuro-Oncology Advances, 2020, 2, vdz051.	0.4	9
99	Parallel fluctuations of psychiatric and neurological symptoms in a patient with multiple sclerosis and bipolar affective disorder. Italian Journal of Neurological Sciences, 1995, 16, 551-553.	0.1	8
100	Deciphering the Labyrinthine System of the Immune Microenvironment in Recurrent Glioblastoma: Recent Original Advances and Lessons from Clinical Immunotherapeutic Approaches. Cancers, 2021, 13, 6156.	1.7	8
101	The <i>EGFRvIII</i> transcriptome in glioblastoma: A meta-omics analysis. Neuro-Oncology, 2022, 24, 429-441.	0.6	7
102	Venous thromboembolism in malignant glioma patients treated by chemoradiotherapy. Neurological Sciences, 2003, 24, 272-272.	0.9	6
103	Short term neurophysiological monitoring in multiple sclerosis bouts. Evaluation of steroid treatment. Italian Journal of Neurological Sciences, 1992, 13, 107-112.	0.1	5
104	Neurological malignancies in neurofibromatosis type 1. Current Opinion in Oncology, 2019, 31, 554-561.	1.1	5
105	Simultaneous Detection of NF1, SPRED1, LZTR1, and NF2 Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients. Genes, 2020, 11, 671.	1.0	5
106	Phenotype analysis of unstimulated lymphocytes and anti-cd3-stimulated proliferating t-cells from cerebrospinal fluid and peripheral blood in patients with multiple sclerosis and other neurological diseases. International Journal of Neuroscience, 1993, 73, 277-285.	0.8	4
107	Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis. Quantitative Imaging in Medicine and Surgery, 2017, 7, 592-597.	1.1	4
108	The noncoding RNA AK127244 in 2p16.3 locus: A new susceptibility region for neuropsychiatric disorders. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 557-562.	1.1	4



#	ARTICLE	IF	CITATIONS
109	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. Journal of Clinical Oncology, 2018, 36, 2047-2047.	0.8	4
110	Role of Physical Training on Immune Function: Preliminary Data. International Journal of Neuroscience, 1990, 51, 249-252.	0.8	3
111	REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS).. Journal of Clinical Oncology, 2017, 35, TPS2085-TPS2085.	0.8	3
112	Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. Journal of Neurosurgery, 2003, 98, 935-6; author reply 936.	0.9	3
113	Central nervous system lymphoma occurring in a patient with neurofibromatosis type 1 (von) Tj ETQq1 1 0.784314 rgBT /Ovrglock 10 T	0.9	2
114	Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series. Neurological Sciences, 2020, 41, 2111-2120.	0.9	2
115	Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients.. Journal of Clinical Oncology, 2019, 37, 2045-2045.	0.8	2
116	The Lipid Asset Is Unbalanced in Peripheral Nerve Sheath Tumors. International Journal of Molecular Sciences, 2022, 23, 61.	1.8	2
117	Cryoglobulinemic neuropathy: case report. Italian Journal of Neurological Sciences, 1988, 9, 391-395.	0.1	1
118	Abstract A031: CD8+T cells fail to form an effector memory in glioblastoma patients treated with dendritic cell immunotherapy in combination with chemotherapy. Cancer Immunology Research, 2016, 4, A031-A031.	1.6	1
119	Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy.. Journal of Clinical Oncology, 2014, 32, 2087-2087.	0.8	1
120	Apparent diffusion coefficient (ADC) decrease to predict longer survival in glioblastoma patients treated by dendritic cell immunotherapy plus standard of care.. Journal of Clinical Oncology, 2017, 35, 2065-2065.	0.8	1
121	The role of the neurologist. Neurological Sciences, 2005, 26, s46-s48.	0.9	0
122	NI-26 * COMPARATIVE ANALYSIS OF THE RANO AND MACDONAD'S CRITERIA IN RECURRENT GLIOBLASTOMA TREATED IN THE RANDOMIZED PHASE II TRIAL AVAREG WITH BEVACIZUMAB OR FOTEMUSTINE.. Neuro-Oncology, 2014, 16, v143-v144.	0.6	0
123	Molecular Markers of Gliomas. , 2009, , 157-177.		0
124	Tumori cerebrali. , 2009, , 297-314.		0
125	Oligoastrocytomas. , 2011, , 2600-2602.		0
126	Abstract 1383: High levels of CD109+ circulating endothelial cells and progenitors as marker of response to bevacizumab and irinotecan in high grade gliomas. , 2012, , .		0



#	ARTICLE	IF	CITATIONS
127	Neurofibromatosis Type 1 and Type 2. , 2015, , 349-354.		0
128	Can Diffusion and Perfusion Weighted Imaging predict 1p/19q codeled lower grade gliomas?. Journal of Clinical Oncology, 2015, 33, 2056-2056.	0.8	0
129	Temozolomide (TMZ) and radiation therapy (RT) combination in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).. Journal of Clinical Oncology, 2015, 33, e13003-e13003.	0.8	0
130	Association of increased survival in glioblastoma patients treated with dendritic cell vaccinations and temozolomide with increased activity of NK cells and ABCC3 expression.. Journal of Clinical Oncology, 2016, 34, 2039-2039.	0.8	0
131	Oligoastrocytomas. , 2017, , 3189-3192.		0
132	Tetanus toxoid pre-conditioning in recurrent glioblastoma treated with dendritic cell immunotherapy is associated to CD8+ T cell response.. Journal of Clinical Oncology, 2018, 36, e14053-e14053.	0.8	0